Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon
Eight months after missing the primary and secondary endpoints on a mid-stage test of its ALS drug, Clene Nanomedicine is back with new data showing that its gold nanocrystal-based candidate decreased risk of death in an open-label extension study.
Clene is attempting to catch up with Amylyx, a biotech with a filing under FDA review and already authorized in Canada, running various studies on its own drug for Lou Gehrig’s disease. But mid-stage results last November put a damper on those ambitions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.